FATE News and Press, Fate Therapeutics Inc. From 06/03/22

Meeting with FDA set for mid-2022 to discuss potential to begin pivotal trial using FT516 for patients with relapsed/refractory diffuse large B-cell lymphoma. If all goes well with FDA meeting for FT516, then a pivotal study should begin in the second half of 2022. FT516 is being ...

SAN DIEGO, June 03, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, to...

Piper Sandler cut its price target (PT) on 17 companies in the biotech space reflecting the recent pullback in the stock and prevailing market conditions. Piper Sandler also noted that biotech valuations have re-rated. Following are the stocks which saw their PT lowered: Gene editing com...

This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion Assets Under Management. After the Q1-2022 13F filings the consensus holdings were updated, 10 stocks were removed and 8 added from the univ...

Gainers: Palo Alto Networks (PANW) +11%. Bioceres Crop Solutions  (BIOX) +7%. VectivBio Holding AG (VECT) +7%. Aveanna Healthcare Holdings (AVAH) +6%. Fate Therapeutics (FATE) +5%. Losers: Foghorn Therapeutics  (FHTX) -26%. Ross Stores (ROST) -23%. Atara Biotherapeutics (A...

This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion Assets Under Management. After the Q4-2021 13F filings the consensus holdings were updated, 7 stocks were removed and 7 added from the unive...

Gainers: REGENXBIO  (RGNX) +8%. Passage Bio (PASG) +6%. Yellow Corporation (YELL) +6%. Fluence Energy (FLNC) +6%. Fate Therapeutics (FATE) +4%. Losers: Cytokinetics (CYTK) -5%. Golden Entertainment GDEN -5%. AlloVir (ALVR) -5%. Arcimoto (FUV) -4%. Canaan  (CAN) -...

SAN DIEGO, May 06, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, tod...

Fate Therapeutics, Inc. (FATE) Q1 2022 Earnings Conference Call May 4, 2022 17:00 ET Company Participants Bob Valamehr - Chief Research & Development Officer Scott Wolchko - Founder, President & Chief Executive Officer Ed Dulac - Chief Financial Officer Wayne Chu - Chief Medical Offic...

Fate Therapeutics press release (NASDAQ:FATE): Q1 GAAP EPS of -$0.68 beats by $0.11. Revenue of $18.4M (+65.2% Y/Y) beats by $9.39M. For further details see: Fate Therapeutics GAAP EPS of -$0.68 beats by $0.11, revenue of $18.4M beats by $9.39M